Potential mechanisms involved in the prevention of neurodegenerative diseases by lithium

CNS Neuroscience and Therapeutics

Volumn 15, Issue 4, 2009, Pages 333-344

  Camins, Antoni ^a   Verdaguer, Ester ^a   Junyent, Felix ^a   Yeste Velasco, Marc ^a   Pelegrí, Carme ^a   Vilaplana, Jordi ^a   Pallás, Mercé ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Alzheimer disease; Autophagy; GSK 3 ; Lithium; Oxidative stress; Parkinson disease

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ARACHIDONIC ACID; BETA BUNGAROTOXIN; BRAIN DERIVED NEUROTROPHIC FACTOR; CYCLIN DEPENDENT KINASE 5; GLUTAMATE RECEPTOR; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3BETA; ISOENZYME; LITHIUM; MAGNESIUM; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2A; N METHYL DEXTRO ASPARTIC ACID RECEPTOR 2B; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN MDM2; PROTEIN P53; RETINOBLASTOMA PROTEIN; STEROID RECEPTOR COACTIVATOR 1; TRANSCRIPTION FACTOR E2F1; TRANSCRIPTION FACTOR FOXO; TYROSINE;

AGING; ALZHEIMER DISEASE; APOPTOSIS; ARACHIDONIC ACID METABOLISM; AUTOPHAGY; BINDING SITE; BIPOLAR DISORDER; BRAIN; CELL CYCLE; CENTRAL NERVOUS SYSTEM; CEREBELLUM NUCLEUS; CLINICAL STUDY; DEGENERATIVE DISEASE; DNA SYNTHESIS; DRUG EFFECT; DRUG MECHANISM; ENZYME INHIBITION; EXCITOTOXICITY; EXPERIMENTAL STUDY; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; MODULATION; MOLECULAR BIOLOGY; NERVE CELL CULTURE; NERVE CELL GROWTH; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; AUTOPHAGY; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LITHIUM COMPOUNDS; MODELS, BIOLOGICAL; NERVE GROWTH FACTOR; NEURODEGENERATIVE DISEASES; NEUROPROTECTIVE AGENTS; OXIDATIVE STRESS;

EID: 70449434550     PISSN: 17555930     EISSN: 17555949     Source Type: Journal    
DOI: 10.1111/j.1755-5949.2009.00086.x     Document Type: Review

References (91)

1. Rowe MK, Chuang DM. Lithium neuroprotection: Molecular mechanisms and clinical implications. Expert Rev Mol Med 2004 6 : 1 18.
2. Zhong J, Lee WH. Lithium: A novel treatment for Alzheimer's disease? Expert Opin Drug Saf 2007 6 : 375 383.
3. Feng HL, Leng Y, Ma CH, Zhang J, Ren M, Chuang DM. Combined lithium and valproate treatment delays disease onset, reduces neurological deficits and prolongs survival in an amyotrophic lateral sclerosis mouse model. Neuroscience 2008 155 : 567 572.
4. Aghdam SY, Barger SW. Glycogen synthase kinase-3 in neurodegeneration and neuroprotection: Lessons from lithium. Curr Alzheimer Res 2007 4 : 21 31.
5. Dunn N, Holmes C, Mullee M. Does lithium therapy protect against the onset of dementia? Alzheimer Dis Assoc Disord 2005 19 : 20 22.
6. Fornai F, Longone P, Ferrucci M, Lenzi P, Isidoro C, Ruggieri S, Paparelli A. Autophagy and amyotrophic lateral sclerosis: The multiple roles of lithium. Autophagy 2008 4 : 527 530.
7. Engel T, Goñi-Oliver P, Lucas JJ, Avila J, Hernández F. Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem 2006 99 : 1445 1455.
8. Bauer M, Alda M, Priller J, Young LT International Group For The Study Of Lithium Treated Patients (IGSLI). Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry 2003 36 (Suppl 3 S250 254.
9. Gould TD, Manji HK. Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology 2005 30 : 1223 1237.
10. Rowe MK, Wiest C, Chuang DM. GSK-3 is a viable potential target for therapeutic intervention in bipolar disorder. Neurosci Biobehav Rev 2007 31 : 920 931.
11. Hongisto V, Smeds N, Brecht S, Herdegen T, Courtney MJ, Coffey ET. Lithium blocks the c-Jun stress response and protects neurons via its action on glycogen synthase kinase 3. Mol Cell Biol 2003 23 : 6027 6036.
12. Linseman DA, Cornejo BJ, Le SS, Meintzer MK, Laessig TA, Bouchard RJ, Heidenreich KA. A myocyte enhancer factor 2D (MEF2D) kinase activated during neuronal apoptosis is a novel target inhibited by lithium. J Neurochem 2003 85 : 1488 1499.
13. Beaulieu JM, Sotnikova TD, Yao WD, Kockeritz L, Woodgett JR, Gainetdinov RR, Caron MG. Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc Natl Acad Sci U S A 2004 101 : 5099 5104.
14. Chuang DM. The antiapoptotic actions of mood stabilizers: Molecular mechanisms and therapeutic potentials. Ann N Y Acad Sci 2005 1053 : 195 204.
15. Beaulieu JM, Gainetdinov RR, Caron MG. The Akt-GSK-3 signaling cascade in the actions of dopamine. Trends Pharmacol Sci 2007 28 : 166 172.
16. Chalecka-Franaszek E, Chuang DM. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc Natl Acad Sci U S A 1999 96 : 8745 8750.
17. Avila J, Hernández F. GSK-3 inhibitors for Alzheimer's disease. Expert Rev Neurother 2007 7 : 1527 1533.
18. + in neuronal cell cultures. J Neural Transm 2007 114 : 405 416.
19. Mora A, Sabio G, González-Polo RA, Cuenda A, Alessi DR, Alonso JC, Fuentes JM, Soler G, Centeno F. Lithium inhibits caspase 3 activation and dephosphorylation of PKB and GSK3induced by K+ deprivation in cerebellar granule cells. J Neurochem 2001 78 : 199 206.
20. Alvarez G, Muñoz-Montaño JR, Satrústegui J, Avila J, Bogónez E, Díaz-Nido J. Regulation of tau phosphorylation and protection against beta-amyloid-induced neurodegeneration by lithium. Possible implications for Alzheimer's disease. Bipolar Disord 2002 4 : 153 165.
21. Engel T, Goñi-Oliver P, Gómez de Barreda E, Lucas JJ, Hernández F, Avila J. Lithium, a potential protective drug in Alzheimer's disease. Neurodegener Dis 2008 5 : 247 249.
22. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, Dewachter I, Van Leuven F. Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 2008 7 : 57 66.
23. Terao T, Nakano H, Inoue Y, Okamoto T, Nakamura J, Iwata N. Lithium and dementia: A preliminary study. Prog Neuropsychopharmacol Biol Psychiatry 2006 30 : 1125 1128.
24. Phiel CJ, Wilson CA, Lee VM, Klein PS. GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature 2003 423 : 435 439.
25. Pérez M, Hernández F, Lim F, Díaz-Nido J, Avila J. Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J Alzheimers Dis 2003 5 : 301 308.
26. Rockenstein E, Torrance M, Adame A, Mante M, Bar-on P, Rose JB, Crews L, Masliah E. Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci 2007 27 : 1981 1991.
27. Feyt C, Kienlen-Campard P, Leroy K, N'Kuli F, Courtoy PJ, Brion JP, Octave JN. Lithium chloride increases the production of amyloid-beta peptide independently from its inhibition of glycogen synthase kinase 3. J Biol Chem 2005 280 : 33220 33227.
28. Wei H, Qin ZH, Senatorov VV, Wei W, Wang Y, Qian Y, Chuang DM. Lithium suppresses excitotoxicity-induced striatal lesions in a rat model of Huntington's disease. Neuroscience 2001 106 : 603 612.
29. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 2004 9 : 371 385.
30. Chuang DM, Manji HK. In search of the Holy Grail for the treatment of neurodegenerative disorders: Has a simple cation been overlooked Biol Psychiatry 2007 62 : 4 6.
31. Verdaguer E, Jordà EG, Alvira D, Jiménez A, Canudas AM, Folch J, Rimbau V, Pallàs M, Camins A. Inhibition of multiple pathways accounts for the antiapoptotic effects of flavopiridol on potassium withdrawal-induced apoptosis in neurons. J Mol Neurosci 2005 26 : 71 84.
32. McShea A, Harris PL, Webster KR, Wahl AF, Smith MA. Abnormal expression of the cell cycle regulators P16 and CDK4 in Alzheimer's disease. Am J Pathol 1997 150 : 1933 1939.
33. Thakur A, Siedlak SL, James SL, Bonda DJ, Rao A, Webber KM, Camins A, Pallàs M, Casadesus G, Lee HG, et al. Retinoblastoma protein phosphorylation at multiple sites is associated with neurofibrillary pathology in Alzheimer disease. Int J Clin Exp Pathol 2008 1 : 134 146.
34. Ahn KW, Joo Y, Choi Y, Kim M, Lee SH, Cha SH, Suh YH, Kim HS. Swedish amyloid precursor protein mutation increases cell cycle-related proteins in vitro and in vivo. J Neurosci Res 2008 86 : 2476 2487.
35. Jordan-Sciutto KL, Malaiyandi LM, Bowser R. Altered distribution of cell cycle transcriptional regulators during Alzheimer disease. J Neuropathol Exp Neurol 2002 61 : 358 367.
36. McShea A, Lee HG, Petersen RB, Casadesus G, Vincent I, Linford NJ, Funk JO, Shapiro RA, Smith MA. Neuronal cell cycle re-entry mediates Alzheimer disease-type changes. Biochim Biophys Acta 2007 1772 : 467 472.
37. Marlatt MW, Lucassen PJ, Perry G, Smith MA, Zhu X. Alzheimer's disease: Cerebrovascular dysfunction, oxidative stress, and advanced clinical therapies. J Alzheimers Dis 2008 15 : 199 210.
38. Hamdane M, Buée L. The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death: The missing link to cell cycle. Biotechnol J 2007 2 : 967 977.
39. Yeste-Velasco M, Folch J, Trullàs R, Abad MA, Enguita M, Pallàs M, Camins A. Glycogen synthase kinase-3 is involved in the regulation of the cell cycle in cerebellar granule cells. Neuropharmacology 2007 53 : 295 307.
40. Tajes M, Gutierrez-Cuesta J, Folch J, Ferrer I, Caballero B, Smith MA, Casadesus G, Camins A, Pallás M. Lithium treatment decreases activities of tau kinases in a murine model of senescence. J Neuropathol Exp Neurol 2008 67 : 612 623.
41. Walz JC, Frey BN, Andreazza AC, Ceresér KM, Cacilhas AA, Valvassori SS, Quevedo J, Kapczinski F. Effects of lithium and valproate on serum and hippocampal neurotrophin-3 levels in an animal model of mania. J Psychiatr Res 2008 42 : 416 421.
42. Nonaka S, Hough CJ, Chuang DM. Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci U S A 1998 95 : 2642 2647.
43. Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration attenuates brain NMDA receptor-initiated signaling via arachidonic acid in unanesthetized rats. Neuropsychopharmacology 2006 31 : 1659 1674.
44. Sarkar S, Floto RA, Berger Z, Imarisio S, Cordenier A, Pasco M, Cook LJ, Rubinsztein DC. Lithium induces autophagy by inhibiting inositol monophosphatase. J Cell Biol 2005 170 : 1101 1111.
45. Fornai F, Longone P, Cafaro L, Kastsiuchenka O, Ferrucci M, Manca ML, Lazzeri G, Spalloni A, Bellio N, Lenzi P, et al. Lithium delays progression of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A 2008 105 : 2052 2057.
46. Klionsky DJ, Abeliovich H, Agostinis P, Agrawal DK, Aliev G, Askew DS, Baba M, Baehrecke EH, Bahr BA, Ballabio A, et al. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy 2008 4 : 151 175.
47. Sarkar S, Rubinsztein DC. Inositol and IP3 levels regulate autophagy: Biology and therapeutic speculations. Autophagy 2006 2 : 132 134.
48. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V Jr., da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, et al. Oxidative stress parameters in unmediated and treated bipolar subjects during initial manic episode: A possible role for lithium antioxidant effects. Neurosci Lett 2007 421 : 33 36.
49. Frey BN, Andreazza AC, Kunz M, Gomes FA, Quevedo J, Salvador M, Gonçalves CA, Kapczinski F. Increased oxidative stress and DNA damage in bipolar disorder: A twin-case report. Prog Neuropsychopharmacol Biol Psychiatry 2007 31 : 283 285.
50. Shao L, Young LT, Wang JF. Chronic treatment with mood stabilizers lithium and valproate prevents excitotoxicity by inhibiting oxidative stress in rat cerebral cortical cells. Biol Psychiatry 2005 58 : 879 884.
51. de Vasconcellos AP, Nieto FB, Crema LM, Diehl LA, de Almeida LM, Prediger ME, da Rocha ER, Dalmaz C. Chronic lithium treatment has antioxidant properties but does not prevent oxidative damage induced by chronic variate stress. Neurochem Res 2006 31 : 1141 1151.
52. Cui J, Shao L, Young LT, Wang JF. Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 2007 144 : 1447 1453.
53. Frey BN, Valvassori SS, Réus GZ, Martins MR, Petronilho FC, Bardini K, Dal-Pizzol F, Kapczinski F, Quevedo J. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 2006 31 : 326 332.
54. King TD, Jope RS. Inhibition of glycogen synthase kinase-3 protects cells from intrinsic but not extrinsic oxidative stress. Neuroreport 2005 16 : 597 601.
55. Schäfer M, Goodenough S, Moosmann B, Behl C. Inhibition of glycogen synthase kinase 3 beta is involved in the resistance to oxidative stress in neuronal HT22 cells. Brain Res 2004 1005 : 84 89.
56. Pizarro JG, Yeste-Velasco M, Rimbau V, Casadesús G, Smith MA, Pallàs M, Folch J, Camins A. Neuroprotective effects of SB-415286 on hydrogen peroxide-induced cell death in B65 rat neuroblastoma cells and neurons. Int J Dev Neurosci 2008 26 : 269 276.
57. Lai JS, Zhao C, Warsh JJ, Li PP. Cytoprotection by lithium and valproate varies between cell types and cellular stresses. Eur J Pharmacol 2006 539 : 18 26.
58. Yeste-Velasco M, Folch J, Jiménez A, Rimbau V, Pallàs M, Camins A. GSK-3 beta inhibition and prevention of mitochondrial apoptosis inducing factorrelease are not involved in the antioxidant properties of SB-415286. Eur J Pharmacol 20087 588 : 239 243.
59. Manji HK, Lenox RH. Signaling: Cellular insights into the pathophysiology of bipolar disorder. Biol Psychiatry 2000 48 : 518 530.
60. Manji HK, Moore GJ, Chen G. Clinical and preclinical evidence for the neurotrophic effects of mood stabilizers: Implications for the pathophysiology and treatment of manic-depressive illness. Biol Psychiatry 1999 48 : 740 754.
61. Chen RW, Chuang DM. Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression. A prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999 274 : 6039 6042.
62. Duan W, Zhu X, Ladenheim B, Yu QS, Guo Z, Oyler J, Cutler RG, Cadet JL, Greig NH, Mattson MP. p53 inhibitors preserve dopamine neurons and motor functio in experimental parkinsonism. Ann Neurol 2002 52 : 597 606.
63. Culmsee C, Zhu X, Yu QS, Chan SL, Camandola S, Guo Z, Greig NH, Mattson MP. A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid beta-peptide. J Neurochem 2001 77 : 220 228.
64. Zhong J, Yang X, Yao W, Lee W. Lithium protects ethanol-induced neuronal apoptosis. Biochem Biophys Res Commun 2006 350 : 905 910.
65. Youdim MB, Arraf Z. Prevention of MPTP (N-methyl-4-phenyl-1,2,3,6- tetrahydropyridine)dopaminergic neurotoxicity in mice by chronic lithium: Involvements of Bcl-2 and Bax. Neuropharmacology 2004 46 : 1130 1140.
66. Senatorov VV, Ren M, Kanai H, Wei H, Chuang DM. Short-term lithium treatment promotes neuronal survival and proliferation in rat striatum infused with quinolinic acid, an excitotoxic model of Huntington's disease. Mol Psychiatry 2004 9 : 371 385.
67. Crespo-Biel N, Camins A, Pallàs M, Canudas AM. Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 2009 56 : 422 428.
68. Jordà EG, Verdaguer E, Canudas AM, Jiménez A, Garcia de Arriba S, Allgaier C, Pallàs M, Camins A. Implication of cyclin-dependent kinase 5 in the neuroprotective properties of lithium. Neuroscience 2005 134 : 1001 1011.
69. Voisine C, Varma H, Walker N, Bates EA, Stockwell BR, Hart AC. Identification of potential therapeutic drugs for Huntington's disease using Caenorhabditis elegans. PLoS ONE 2007 2 : e504.
70. Hamdane M, Buée L. The complex p25/Cdk5 kinase in neurofibrillary degeneration and neuronal death: The missing link to cell cycle. Biotechnol J 2007 2 : 967 977.
71. Camins A, Pallas M, Silvestre JS. Apoptotic mechanisms involved in neurodegenerative diseases: Experimental and therapeutic approaches. Methods Find Exp Clin Pharmacol 2008 30 : 43 65.
72. Dou H, Ellison B, Bradley J, Kasiyanov A, Poluektova LY, Xiong H, Maggirwar S, Dewhurst S, Gelbard HA, Gendelman HE. Neuroprotective mechanisms of lithium in murine human immunodeficiency virus-1 encephalitis. J Neurosci 2005 25 : 8375 8385.
73. Tseng WP, Lin-Shiau SY. Long-term lithium treatment prevents neurotoxic effects of beta-bungarotoxin in primary cultured neurons. J Neurosci Res 2002 69 : 633 641.
74. Huang X, Lei Z, El-Mallakh RS. Lithium normalizes elevated intracellular sodium. Bipolar Disord 2007 9 : 298 300.
75. Hennion JP, el-Masri MA, Huff MO, el-Mailakh RS. Evaluation of neuroprotection by lithium and valproic acid against ouabain-induced cell damage. Bipolar Disord 2002 4 : 201 206.
76. Mason RP, Leeds PR, Jacob RF, Hough CJ, Zhang KG, Mason PE, Chuang DM. Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells. J Neurochem 1999 72 : 1448 1456.
77. Goodenough S, Conrad S, Skutella T, Behl C. Inactivation of glycogen synthase kinase-3beta protects against kainic acid-induced neurotoxicity in vivo. Brain Res 2004 1026 : 116 125.
78. Plant KE, Anderson E, Simecek N, Brown R, Forster S, Spinks J, Toms N, Gibson GG, Lyon J, Plant N. The neuroprotective action of the mood stabilizing drugs lithium chloride and sodium valproate is mediated through the up-regulation of the homeodomain protein Six1. Toxicol Appl Pharmacol 2009 235 : 124 134.
79. Inouye M, Yamamura H, Nakano A. Lithium delays the radiation-induced apoptotic process in external granule cells of mouse cerebellum. J Radiat Res 1995 36 : 203 208.
80. Pascual T, Gonzalez JL. A protective effect of lithium on rat behaviour altered by ibotenic acid lesions of the basal forebrain cholinergic system. Brain Res 1995 695 : 289 292.
81. Sparapani M, Virgili M, Ortali F, Contestabile A. Effects of chronic lithium treatment on ornithine decarboxylase induction and excitotoxic neuropathology in the rat. Brain Res 1997 765 : 164 168.
82. Kim YR, van Meer MP, Tejima E, Murata Y, Mandeville JB, Dai G, Chuang DM, Rosen BR, Lo EH. Functional MRI of delayed chronic lithium treatment in rat focal cerebral ischemia. Stroke 2008 39 : 439 447.
83. Jordà EG, Verdaguer E, Morano A, Jiménez A, Canudas AM, Camins A, Pallàs M. Lithium prevents colchicine-induced apoptosis in rat cerebellar granule neurons. Bipolar Disord 2004 6 : 144 149. (Pubitemid 38443568)
84. Sureda FX, Gutierrez-Cuesta J, Romeu M, Mulero M, Camins A, Pallàs M. Changes in oxidative stress parameters and neurodegeneration markers in the brain of the senescence-accelerated mice SAMP-8. Exp Gerontol 2006 41 : 360 367.
85. Pelegrí C, Canudas AM, del Valle J, Casadesus G, Smith MA, Camins A, Pallàs M, Vilaplana J. Increased permeability of blood-brain barrier on the hippocampus of a murine model of senescence. Mech Ageing Dev 2007 128 : 522 528.
86. Pérez M, Rojo AI, Wandosell F, Díaz-Nido J, Avila J. Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3. Biochem J 2003 372 : 129 136.
87. McColl G, Killilea DW, Hubbard AE, Vantipalli MC, Melov S, Lithgow GJ. Pharmacogenetic analysis of lithium-induced delayed aging in Caenorhabditis elegans. J Biol Chem 2008 283 : 350 357.
88. Greer EL, Brunet A. FOXO transcription factors in ageing and cancer. Acta Physiol (Oxf) 2008 192 : 19 28.
89. Hwangbo DS, Gershman B, Tu MP, Palmer M, Tatar M. Drosophila dFOXO controls lifespan and regulates insulin signalling in brain and fat body. Nature 2004 429 : 562 566.
90. Greer EL, Brunet A. FOXO transcription factors at the interface between longevity and tumor suppression. Oncogene 2005 24 : 7410 7425.
91. Tajes M, Yeste-Velasco M, Zhu X, Chou SP, Smith MA, Pallàs M, Camins A, Casadesús G. Activation of Akt by lithium: Pro-survival pathways in aging. Mech Ageing Dev 2009 130 253 261.